文献速递肝病

停用富马酸丙酚替诺福韦后HBeAg阴性患者复发率高于恩替卡韦或富马酸替诺福韦二吡呋酯

Higher Relapse Rate in HBeAg-Negative Patients After Cessation of Tenofovir Alafenamide Compared With Entecavir or Tenofovir Disoproxil Fumarate.
PubMed 文献 · Am J Gastroenterol · 2025-01-17

研究纳入805例无肝硬化HBeAg阴性患者,分别停用恩替卡韦(n=406)、TDF(n=260)或TAF(n=139),经倾向性评分匹配分析。停用TAF组96周病毒学复发、临床复发和再治疗累积发生率均高于停用恩替卡韦或TDF组,且临床复发时间更早。多因素分析显示TAF治疗是复发的独立危险因素。

要点

  • 停用TAF组96周病毒学复发率89.6%、临床复发率70.3%、再治疗率59.2%,均高于停用恩替卡韦或TDF组。
  • 停用TAF患者临床复发中位时间14周,早于停用恩替卡韦(57周)或TDF(26周)。
  • TAF治疗相比恩替卡韦或TDF是病毒学复发、临床复发和再治疗的独立危险因素。

核心结论

  • 停用TAF治疗的患者HBV复发率高于停用恩替卡韦或TDF的 comparable 患者,且复发时间更早。

研究设计与样本

  • 共纳入805例无肝硬化HBeAg阴性患者,接受恩替卡韦(n=406)、TDF(n=260)或TAF(n=139)治疗,采用倾向性评分匹配法消除临床特征显著差异。

主要发现

  • 停用TAF组96周病毒学复发、临床复发和再治疗累积发生率分别为89.6%、70.3%和59.2%,高于停用恩替卡韦组(65.9%、42.8%、28.8%)和停用TDF组(73.7%、49.8%、35.7%)。
  • 停用TAF患者临床复发中位时间14周,早于停用恩替卡韦(57周)或TDF(26周),倾向性评分匹配后结果持续。
  • 多因素分析表明,与恩替卡韦或TDF相比,TAF治疗是病毒学复发、临床复发和再治疗的独立危险因素。
  • 停用TAF组治疗结束时HBsAg水平可预测病毒学复发但不能预测临床复发,且该组临床复发时重型肝炎发生率低于停用TDF组。
  • 恩替卡韦、TDF和TAF组肝失代偿率无显著差异。

临床怎么用

  • 停用TAF后需要密切监测,尤其是在前3个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is limited information comparing the off-therapy relapse rates of patients discontinued tenofovir alafenamide (TAF) to those stopping entecavir or tenofovir disoproxil fumarate (TDF). METHODS: A total of 805 hepatitis B e antigen-negative patients without cirrhosis receiving entecavir (n = 406), TDF (n = 260), or TAF (n = 139) were enrolled. Propensity score matching method was applied to eliminate the significant differences in clinical characteristics. RESULTS: The cumulative incidences of virological relapse, clinical relapse, and retreatment at 96 weeks were higher in the off-TAF group (89.6%, 70.3%, and 59.2%, respectively) than that in the off-entecavir group (65.9%, 42.8%, and 28.8%, respectively) or the off-TDF group (73.7%, 49.8%, and 35.7%, respectively). The median time to clinical relapse was much earlier for off-TAF patients than for off-entecavir or off-TDF (median 14, 57, and 26 weeks, respectively), and these findings persisted even after propensity score matching. Multivariate analysis indicated that TAF therapy was an independent risk factor of virological relapse, clinical relapse, and retreatment when compared with entecavir or TDF. Hepatitis B surface antigen levels at end of treatment were predictive of virological, but not clinical, relapse in the off-TAF group, although this group had a lower rate of severe hepatitis on clinical relapse than the off-TDF group. Finally, there was no significant difference in the hepatic decompensation rate among the entecavir, TDF, and TAF groups. DISCUSSION: There is an earlier and higher hepatitis B virus relapse rate in patients who discontinue TAF therapy than in comparable patients discontinuing entecavir or TDF therapy. Close monitoring is necessary after TAF withdrawal, particularly in the first 3 months.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Fang HW, Jeng WJ, Hu TH, et al. Higher Relapse Rate in HBeAg-Negative Patients After Cessation of Tenofovir Alafenamide Compared With Entecavir or Tenofovir Disoproxil Fumarate. Am J Gastroenterol. 2025. PMID: 39820130. doi:10.14309/ajg.0000000000003324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。